Schizophrenia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Schizophrenia (US)

Schizophrenia is a psychiatric disease that usually requires long-term treatment. It typically manifests in early adulthood, presenting as a chronic condition characterized by a recurring pattern of relapse and remission. The primary goals of treatment are to reduce the frequency and severity of psychotic episodes, maintain the reduction in these symptoms over the long term, and improve patients’ functional capacity. It is a highly drug-treated condition that uses an array of medications, including atypical and typical antipsychotics, resulting in a complex treatment algorithm. Although this drug market is entrenched with generic therapies, the need for longer-acting agents and more-effective / safer drugs allows branded agents (e.g., Lundbeck/Otsuka’s Abilify Asimtufii, Teva’s Uzedy, Intra-Cellular Therapies’ Caplyta) to be incorporated into the treatment algorithm. Our Treatment Algorithms study uses national patient-level claims data to explore the uptake of key therapies in newly diagnosed and recently treated patients, providing insight into the current treatment of schizophrenia.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed schizophrenia patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed schizophrenia patients?
• How have orals (e.g., Caplyta, Lybalvi, Vraylar) and long-acting injectables (e.g., Abilify Asimtufii, Aristada, Invega Sustenna, Invega Hafyera) been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of schizophrenia patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of schizophrenia patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Real-world data: Longitudinal patient-level claims data analysis

Key drugs covered: Abilify Maintena, Abilify Asimtufii, Invega Hafyera, Aristada, Invega Sustenna, Rexulti, Uzedy, olanzapine, Vraylar, Caplyta, Lybalvi, others

Key analyses:

• Brand / therapy usage across longitudinal patient sample.
• Newly diagnosed patient analysis.
• Treatment initiation and progression.
• Line of therapy analysis.
• Combination therapy analysis.
• Source of business for recently treated patients.
• Persistency and compliance analysis.
• Product-level patient flow charts.